Non-Hodgkin Lymphoma Therapeutics Market Research Report 2020 Radiant Insights, Inc
GBI Research, the leading business intelligence provider, has released its latest research, 'Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting', which provides in-depth insights into the indication. It gives an estimation of market size for 2013 along with forecasts until 2020 for the Asia-Pacific (APAC) region, which comprises Australia, China, India and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Non-Hodgkin Lymphoma (NHL). Read Complete Report with TOC @ http://www.radiantinsights.com/research/non-hodgkin-lymphoma-therapeutics-in-asia-pacific-markets-to-2020-novel-technologies-show-considerable-promise-in-relapsed-refractory-setting The market in the APAC region was worth an estimated $1.1 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.6% to $1.7 billion in 2020. The expected launches of promising drugs, including novel protein kinase inhibitors and next-generation monoclonal antibodies, as well as the continued use of the current blockbuster, Rituxan/Mabthera, will be the key growth drivers. The launch of premium-priced novel glycol-engineered antibody; obinutuzumab; kinase inhibitors including idelalisib and ibrutinib; and the mTOR inhibitor everolimus are also expected to have a significant impact, as is the anticipated approval of immunomodulatory agent Revlimid as a maintenance setting. An increasingly aging population and a year-on-year increase in the number of incident cases will provide an additional boost. However, the recent implementation of a price ceiling on essential drugs in India; anticipated pricing restrictions in China; and low access, penetration and price erosion due to generic dominance, especially in India, stand to curtail the APAC NHL market.
GBI Research, the leading business intelligence provider, has released its latest research, 'Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting', which provides in-depth insights into the indication. It gives an estimation of market size for 2013 along with forecasts until 2020 for the Asia-Pacific (APAC) region, which comprises Australia, China, India and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Non-Hodgkin Lymphoma (NHL).
Read Complete Report with TOC @ http://www.radiantinsights.com/research/non-hodgkin-lymphoma-therapeutics-in-asia-pacific-markets-to-2020-novel-technologies-show-considerable-promise-in-relapsed-refractory-setting
The market in the APAC region was worth an estimated $1.1 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.6% to $1.7 billion in 2020. The expected launches of promising drugs, including novel protein kinase inhibitors and next-generation monoclonal antibodies, as well as the continued use of the current blockbuster, Rituxan/Mabthera, will be the key growth drivers. The launch of premium-priced novel glycol-engineered antibody; obinutuzumab; kinase inhibitors including idelalisib and ibrutinib; and the mTOR inhibitor everolimus are also expected to have a significant impact, as is the anticipated approval of immunomodulatory agent Revlimid as a maintenance setting. An increasingly aging population and a year-on-year increase in the number of incident cases will provide an additional boost. However, the recent implementation of a price ceiling on essential drugs in India; anticipated pricing restrictions in China; and low access, penetration and price erosion due to generic dominance, especially in India, stand to curtail the APAC NHL market.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
6 Deals and Strategic Consolidations 65<br />
6.1 Major Co-development Deals 67<br />
6.1.1 Roche Signs an Agreement with GlycArt and Genentech 68<br />
6.1.2 Cell <strong>Therapeutics</strong> Enters Agreement with Bayer 68<br />
6.1.3 Chugai Enters Co-development Agreement with Nippon Shinyaku for GA101 68<br />
6.1.4 GlaxoSmithKline Enters Co-development Agreement with Genmab 69<br />
6.1.5 Biogen Idec Enters Co-development Agreement with Genentech 69<br />
6.1.6 Seattle Genetics Enters Co-development Agreement with Millennium 69<br />
6.2 Major Licensing Deals 69<br />
Read Complete <strong>Report</strong> with TOC @ http://www.radiantinsights.com/research/non-hodgkinlymphoma-therapeutics-in-asia-pacific-markets-to-<strong>2020</strong>-novel-technologies-show-considerablepromise-in-relapsed-refractory-setting<br />
6.2.1 Spectrum Enters Licensing Agreement with Bayer for Zevalin 70<br />
6.2.2 Janssen Biotech Enters Licensing Agreement with Pharmacyclics for PCI-32765 70<br />
6.2.3 Lundbeck Enters Licensing Agreement with Cephalon 71<br />
6.2.4 TG <strong>Therapeutics</strong> Enters Licensing Agreement with Ildong for Ublituximab 71<br />
6.2.5 Provenance Enters Licensing Agreement with Merck Serono 71<br />
6.2.6 Cephalon Enters Licensing Agreement with SymBio 71<br />
6.2.7 Genentech Enters Licensing Agreement with Seattle Genetics 71<br />
7 Appendix 72<br />
7.1 <strong>Market</strong> Definitions 72<br />
7.2 Abbreviations 72<br />
7.3 Bibliography 75<br />
7.4 Pipeline Tables 78<br />
7.4.1 Discovery 78<br />
7.4.2 Preclinical 79<br />
7.4.3 Investigational New Drug-Filed 81
Change language